TITLE

The Emergency Drug Release Program: regulatory aspects of new drug access in Canada

AUTHOR(S)
Gilron, Ian
PUB. DATE
April 1993
SOURCE
CMAJ: Canadian Medical Association Journal;4/1/1993, Vol. 148 Issue 7, p1151
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
35491862

 

Related Articles

  • National Seminar on "Regulatory and Quality Aspects of Herbal Drugs and Botanicals". Ahmad, Sayeed // Journal of Pharmacy & Bioallied Sciences;Oct-Dec2015, Vol. 7 Issue 4, p245 

    Information about herbal drugs and botanicals discussed at a seminar "Regulatory and Quality Aspects of Herbal Drugs and Botanicals" sponsored by the University Grants Commission‑Special Assistance Program of India is presented. Topics include the research in Pharmacognosy and...

  • Pricing Under Microscope.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p64 

    The article reports on the release of the discussion paper "Generic Drug Pricing and Access in Canada: What are the Implications?" by the Health Council of Canada.

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;12/8/2012, Issue 668, p9 

    This section offers health regulatory and healthcare news briefs. "Visiongain" predicts that the value of India's medical device market will increase to 11 U.S. billion dollars by 2023 from 3 billion U.S. dollars in 2011. The Canadian Diabetes Association (CDA) released a report recommending the...

  • Guidelines on emergency provision of controlled drugs released.  // BMJ: British Medical Journal (International Edition);02/22/97, Vol. 314 Issue 7080, p536 

    Reports on the World Health Organization's release of guidelines to help national authorities simplify their regulatory procedures for donations of controlled drugs in emergencies.

  • O uso de drogas ainda experimentais em assistência: extensão de pesquisa, uso compassivo e acesso expandido. Goldim, José Roberto // Revista Panamericana de Salud Publica;Mar2008, Vol. 23 Issue 3, p198 

    This article describes the methodological, regulatory, and ethical aspects of the different therapeutic uses of investigational drugs-research extension, compassionate use, and expanded access. Worldwide, the principle challenges of this kind of treatment are: setting minimum quality standards...

  • Global partnerships for health.  // WHO Drug Information;1999, Vol. 13 Issue 1, p1 

    Discusses ways by which access to affordable, innovative and essential drugs can be improved through research in the pharmaceutical industry. Drug strategy revision; Action program on essential drugs; Norms, standards and regulations for implementation by regulatory authorities.

  • New directions in drug approval. Lexchin, Joel // CMAJ: Canadian Medical Association Journal;8/3/2004, Vol. 171 Issue 3, p229 

    Reports on the changes that are underway in Canada's drug regulatory system which will have significant implications for how new drugs are approved and how well Health Canada monitors the safety of drugs already on the market. New direction in regulatory activities enunciated by the Throne...

  • Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998. Rawson, Nigel S.B.; Rawson, N S // CMAJ: Canadian Medical Association Journal;2/22/2000, Vol. 162 Issue 4, p501 

    Background: The timeliness with which national regulatory agencies approve new drugs for marketing affects health care professionals and patients. An unnecessarily long approval process delays access to new medications that may improve patients' health status. The author compared...

  • Duloxetine sole suspected drug in cases of serotonin syndrome.  // Reactions Weekly;1/11/2014, Issue 1483, p2 

    The article reports on the association of duloxetine with emergence of serotonin syndrome according to a report released by Therapeutic Goods Administraton (TGA), a regulatory agency for medical drugs and devices in Australia.

  • IND monitoring program wins protection award.  // IRB Advisor;Apr2009, Vol. 9 Issue 4, p42 

    The article announces that the Investigational New Drug (IND) Regulatory and Monitoring Program won the 2008 Award for Excellence in Human Research Protection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics